Big Pharma company, Bristol-Myers Squibb, has become pharma partners with Santaris in order to research and co-develop novel medicines using locked nucleic acid drug platforms.

Sometimes, it’s what you don’t say that gets investors whipped up. Heated rumors of a possible takeover of Switzerland’s Actelion, a Roche spinout, turned red hot after the company noted that it is always engaged in routine talks with other biopharma companies.